EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice

Maura Corsetti iD, Sylvie Forestier, Marcel Jiménez

Neurogastroenterology & Motility · 2023-04 · 35 (4)

DOI: 10.1111/nmo.14451 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 16.08.2022. Verfasst von Maura Corsetti und 2 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham Digestive Di…. Hauptthemen laut MEDLINE: Scopolamine, Butylscopolammonium Bromide. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyoscine butylbromide (HBB) has been available for use as an antispasmodic since 1951 and is indicated for the treatment of abdominal pain associated with cramps. A previous review in 2007 summarized the evidence on the mode of action of HBB in vitro and in vivo in both animal and human studies. However, since then, novel publications have appeared within the literature and also our knowledge of what represents normal motility in humans has evolved.

Purpose

This review is the result of the collaboration between a basic scientist and clinicians with the aim of providing an updated overview of the mechanisms of action of HBB and its clinical efficacy to guide not only use in clinical practice, but also future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ScopolamineButylscopolammonium BromideAnimalsHumansParasympatholyticsAbdominal PainHydrocarbons, Brominated

Stichwörter der Autor:innen

colongastrointestinal tracthyoscine butylbromidelarge intestinepharmacologic actionsscopolamine

Substanzen

ScopolamineButylscopolammonium BromideParasympatholyticsbutyl bromideHydrocarbons, Brominated

Autor:innen und Institutionen

  • NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingha…
  • Sanofi Consumer Healthcare, Sanofi, Gentilly, France.
  • Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Barcelona, Spain.

ORCID-Profile: Maura Corsetti

Zitieren

APA

Corsetti, M., Forestier, S., & Jiménez, M. (2023). Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice. Neurogastroenterology & Motility, 35(4). https://doi.org/10.1111/nmo.14451

Vancouver

Corsetti M, Forestier S, Jiménez M. Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice. Neurogastroenterology & Motility. 2023;35(4). doi:10.1111/nmo.14451

BibTeX
@article{Corsetti2023,
  author = {Corsetti, Maura and Forestier, Sylvie and Jiménez, Marcel},
  title = {Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice},
  journal = {Neurogastroenterology & Motility},
  year = {2023},
  volume = {35},
  number = {4},
  doi = {10.1111/nmo.14451}
}
Kostenlos starten →